Abstract
The aim of the present manuscript is to discuss on potential pros and cons of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as glucose-lowering agents during COVID-19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID-19 infection, with or even without diabetes mellitus type 2. Besides being important glucose-lowering agents, GLP-1RAs pose promising anti-inflammatory and anti-obesogenic properties, pulmonary protective effects, as well as beneficial impact on gut microbiome composition. Hence, taking everything previously mentioned into consideration, GLP-1RAs seem to be potential candidates for the treatment of patients, affected by COVID-19 infection, with or even without type 2 diabetes mellitus, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
Keywords: antidiabetics; coronavirus; diabetes mellitus; glucagon-like peptide 1; obesity.
【저자키워드】 coronavirus, obesity, Diabetes Mellitus, antidiabetics, glucagon-like peptide 1, 【초록키워드】 Treatment, Anti-inflammatory, COVID-19 pandemic, obesity, Diabetes Mellitus, peptide, Type 2 diabetes mellitus, diabetes, Protective effects, COVID-19 infection, receptor, patients, Glucose, Diabetes mellitus type 2, glucagon-like peptide 1, Glucagon-like peptide-1, glucagon-like peptide, glucagon, candidate, agonist, manuscript, everything, gut microbiome composition, affected, evaluate, diabete, type 2 diabete, 【제목키워드】 receptor, agonist, Friend,